FDA Advisory Panel Skeptical on Up-Scheduling Hydrocodone

The Drug Enforcement Agency (DEA) has asked for the FDA’s opinion on whether to reclassify hydrocodone from schedule III to the stricter schedule II category, but briefing documents show the agency is not sold on the idea.
Drug Industry Daily